A dual-responsive doxorubicin-indoximod conjugate for programmed chemoimmunotherapy.
Zhaoxuan Yang1, Jiaqi Huang1, Yaying Lin1
1Fujian Provincial Key Laboratory of Chemical Biology, The MOE Key Laboratory of Spectrochemical Analysis & Instrumentation, and Department of Chemical Biology, College of Chemistry and Chemical Engineering, Xiamen University Xiamen 361005 China China hylin007@xmu.edu.cn jhgao@xmu.edu.cn.
RSC Chemical Biology
|July 22, 2022
Summary
This study introduces a dual-responsive drug conjugate for chemoimmunotherapy, releasing doxorubicin and indoximod to enhance immune response and inhibit tumor growth.
Area of Science:
- Drug Delivery
- Cancer Immunotherapy
- Medicinal Chemistry
Background:
- Chemotherapy and immunotherapy are crucial cancer treatment modalities.
- Developing targeted drug delivery systems can improve therapeutic efficacy and reduce side effects.
- Programmed drug release systems offer potential for synergistic treatment strategies.
Purpose of the Study:
- To develop and characterize a dual-responsive conjugate for combined chemotherapy and immunotherapy.
- To investigate the stimuli-triggered release of doxorubicin and indoximod from the conjugate.
- To evaluate the synergistic effects of the conjugate on anti-tumor immune response and tumor growth inhibition.
Main Methods:
- Synthesis and characterization of the doxorubicin-indoximod conjugate (DOXIND).
- In vitro studies to assess drug release kinetics and cellular effects.
- In vivo experiments in tumor models to evaluate therapeutic efficacy and immune modulation.
Main Results:
- The DOXIND conjugate demonstrated successful dual-responsive drug release upon specific stimuli.
- In vitro assays showed potent cytotoxic effects of released doxorubicin and immune-modulating activity of indoximod.
- In vivo studies confirmed significant tumor growth inhibition and enhanced anti-tumor immune responses.
Conclusions:
- The dual-responsive DOXIND conjugate is a promising platform for programmed chemoimmunotherapy.
- This approach enables synergistic cancer treatment by combining chemotherapy and immunotherapy.
- Further investigation is warranted to explore its clinical applicability.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K